English
Back
Download
Log in to access Online Inquiry
Back to the Top

NEWS

Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting
Genprex announced that its research collaborators at Meharry Medical College will present positive preclinical data on Reqorsa® Gene Therapy at the 39th Annual Society for Immunotherapy of Cancer Meeting in Houston, Texas, from November 6-10, 2024. The poster presentation will focus on Reqorsa's ability to modulate in vivo immune responses against cancers.

The study evaluates TUSC2's role in modulating immune responses in cancer. TUSC2 is the tumor suppressor gene used in REQORSA, which consists of a TUSC2 gene expressing plasmid encapsulated in non-viral lipid-based nanoparticles. REQORSA is designed to deliver the functioning TUSC2 gene to cancer cells while minimizing uptake by normal tissue.

Ryan Confer, President and CEO of Genprex, expressed enthusiasm about the growing preclinical evidence supporting REQORSA's potential in treating various cancers and the opportunity to present these findings at the prestigious cancer meeting.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
5309 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    6443
    Followers
    43
    Following
    69K
    Visitors
    Follow